TP53 and prostate cancer: In human prostate cancer LNCaP (a wild-type p53) cells, delphinidin causes caspase-mediated apoptosis, leading to HDAC3 inactivation and cleavage, by increasing caspase-3, caspase-7, and caspase-8 activity and by activating and stabilizing p53 in a dose- and time-dependent manner.